Waters Corporation heads into its August 4 earnings with a subtle but persistent disconnect: short interest has been quietly building for six weeks while analysts are actively raising targets and reinstating coverage.
The short interest story is modest but directional. At 7.6% of the free float, shorts are not at an alarming level — but the trend is clear. From roughly 3.95 million shares in late May, short positions have climbed to 4.54 million, a gain of around 7% over the period. The move has been gradual and steady, with almost no reversal days in the history. That kind of incremental accumulation, without a dramatic catalyst, points to a methodical bearish thesis rather than a speculative pile-in. The ORTEX short score has edged up to 43 from 41.8 a week ago, consistent with the direction of travel.
The borrow market tells a completely different story, and it matters. Availability remains extremely loose — roughly 934% of short interest is available to borrow, well above even the 52-week low of 736%. Borrow cost is just under 0.5%, roughly unchanged on the week in real terms. There is no squeeze dynamic here. Despite the short position growing, the lending pool is so deep that new shorts face no friction entering the trade. Options positioning adds a mild cautionary note: the put/call ratio has nudged to 0.70, a touch above its 20-day average of 0.65, a one-standard-deviation move that reads as slightly more defensive than usual rather than genuinely alarmed. Positioning looks measured rather than polarised.
The Street, meanwhile, has been tilting constructively bullish. Evercore ISI raised its target to $410 from $380 this week, maintaining an Outperform. Guggenheim reiterated its Buy and $440 target Tuesday. Bernstein reinstated coverage late June with an Outperform at $435. Add in earlier initiations and target lifts from Wolfe Research, Barclays, HSBC, and B of A Securities — most in the $400–$440 range — and the consensus message is clear: the Street sees upside from the current $374.93 price, with a mean target near $404. The one holdout is Wells Fargo's Equal-Weight at $370, barely at the current price. The forward EPS momentum factor ranks in the 84th percentile on 12-month-forward year-on-year improvement, and analyst recommendation divergence scores in the 99th percentile — an almost universal tilt toward positive ratings. The valuation is not cheap (P/E near 24x, EV/EBITDA near 16.7x), but both multiples have expanded modestly over the past month, consistent with improving earnings expectations rather than multiple compression.
The institutional picture reinforces the constructive tone. BlackRock reported adding over 3.1 million shares through end-June, taking its stake to 8.7% of the company. T. Rowe Price added nearly 5 million shares through May, building to 5.9% of shares. MFS built to 4.7%. These are substantial position increases from major long-only holders, which helps explain why the borrow market is so well-supplied and squeeze risk so low — the stock is well-owned and actively lent. Insider activity, by contrast, has been routine: a minor director buy back in March at prices well below current levels, and small routine executive sales since then. No signal either way from the C-suite.
The Q1 print in May delivered a 15.8% one-day gain, with the five-day follow-through adding another point on top. That was the clearest recent evidence of what a beat means for this name — a sharp, sustained re-rating. With Q2 results due August 4, the question is whether the analytical instrumentation demand recovery that drove May's beat has continued into June, and whether management's guidance is credible enough to hold the newly higher analyst targets.
See the live data behind this article on ORTEX.
Open WAT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
